Vital Signs Podcast: Why this clinical-stage oncology company is “first in class”

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.

In this episode, Nadine chats with Prescient Therapeutics (ASX:PTX) CEO James McDonnell.

Prescient is focused on developing new therapies for cancers with unmet needs.

The company’s lead compound, PTX-100, is described as “first in class”.

Tune in to this episode to hear how the compound works, why McDonnell believes it’s one of a kind, and more.

This podcast was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.